For over a decade, GenoScreen has been committed to the fight against tuberculosis (TB), one of the deadliest infectious diseases in the world. The company's journey began with the groundbreaking development of MIRU-VNTR typing kits in 2013 which marked a turning point in TB research and control by enabling rapid and accurate identification of TB strains. This breakthrough technology provided an unparalleled level of resolution in characterizing TB strains, essential for the management and control of TB outbreaks, allowing researchers and public health authorities to track the spread of the disease more efficiently and prevent further outbreaks.
Continuing on this innovation path, GenoScreen developed the Deeplex® Myc-TB assay, one of the most comprehensive CE-IVD kit to test drug susceptibility and resistance of Mycobacterium tuberculosis, the bacterium causing TB. The cutting-edge technology of this kit enables quicker and more accurate diagnosis of tuberculosis and its drug resistance, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). By providing physicians and researchers with a highly reliable and efficient diagnostic tool, GenoScreen helps to ensure that patients receive the best possible treatment and that the spread of TB is controlled as effectively as possible. The company is continuously striving for improvement and optimization, and is currently working on a new version of the kit, even more extensive.
GenoScreen's commitment to fight tuberculosis goes beyond the development and commercialization of innovative tools. They closely collaborate with genomics and healthcare leading companies such as Illumina or Cerba, NGOs and supranational reference labs to leverage the strengths of each entity, facilitating the implementation of innovative solutions in countries with the highest needs. Through these collaborations, GenoScreen and its employees contributes to the battle against TB and support the goal of the WHO to eradicate TB by 2035.
“At GenoScreen, we consider investing in and getting involved in the fight against tuberculosis to be more than just our job, but part of our core values and mission. We believe that through our ongoing R&D, strategic partnerships, and unwavering dedication, we can help to finally eliminate this devastating infection and improve the lives of millions of people living with TB and other infectious diseases.” André Tordeux, CEO.
Yes we can, end TB!